Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$0.51 USD
+0.02 (4.10%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $0.50 -0.01 (-1.98%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Purple Biotech Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 15 | 32 | 47 | 58 | 6 |
Receivables | 0 | 1 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 1 | 1 | 2 |
Total Current Assets | 16 | 33 | 48 | 59 | 8 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 28 | 21 | 20 | 20 | 6 |
Deposits & Other Assets | 0 | 0 | 0 | 3 | 0 |
Total Assets | 44 | 55 | 70 | 84 | 15 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 5 | 3 | 2 | 2 |
Total Current Liabilities | 7 | 7 | 4 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 8 | 5 | 4 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 133 | 126 | 124 | 119 | 47 |
Retained Earnings | -137 | -118 | -96 | -78 | -50 |
Other Equity | 39 | 38 | 37 | 38 | 13 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 34 | 47 | 65 | 80 | 11 |
Total Liabilities & Shareholder's Equity | 44 | 55 | 70 | 84 | 15 |
Total Common Equity | 34 | 47 | 65 | 80 | 11 |
Shares Outstanding | 25.20 | 18.40 | 25.90 | 15.70 | 1.90 |
Book Value Per Share | 1.36 | 2.56 | 2.51 | 5.08 | 5.72 |
Fiscal Year End for Purple Biotech Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 15 | 16 | 18 | 23 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 1 | 1 | 1 |
Total Current Assets | NA | 16 | 17 | 19 | 24 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 28 | 28 | 28 | 28 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 44 | 45 | 48 | 53 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 3 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 3 | 3 | 3 |
Total Current Liabilities | NA | 7 | 6 | 5 | 6 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 10 | 7 | 5 | 6 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 133 | 133 | 132 | 131 |
Retained Earnings | NA | -137 | -133 | -128 | -122 |
Other Equity | NA | 39 | 38 | 38 | 39 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 34 | 39 | 43 | 47 |
Total Liabilities & Shareholder's Equity | NA | 44 | 45 | 48 | 53 |
Total Common Equity | 0 | 34 | 39 | 43 | 47 |
Shares Outstanding | 25.20 | 25.20 | 22.00 | 20.80 | 20.80 |
Book Value Per Share | 0.00 | 1.36 | 1.76 | 2.06 | 2.26 |